ManagementDr Reddy's Lab rises 2.3%
The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters.
- Dr Reddy"s to strengthen domestic biz - Dr Reddy"s plans to launch Lipitor"s generic version in US - Dr Reddy"s develops generic version of Pfizer"s Lipitor - Intermediate trend reversal confirmed - DRL net doubles to Rs 217 cr - Dr Reddy"s forays into transdermal patch segment
The company which conducted the study to determine the efficacy and safety of the drug, with Rheoscience — a subsidiary of Nordic Bioscience said, it met its primary endpoint of reducing HbA1c or Glycoslated haemoglobin molecule, which indicates glucose level in blood. Besides, the oral anti-diabetic drug also showed effective results on fasting plasma glucose, oedeman and weight gain & body composition.